 Chloride Channel Agonists
"Chloride Channel Agonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of drugs that stimulate chloride ion influx through cell membrane channels.
| Descriptor ID |
D065101
|
| MeSH Number(s) |
D27.505.519.562.311
|
| Concept/Terms |
Chloride Channel Agonists- Chloride Channel Agonists
- Agonists, Chloride Channel
- Channel Agonists, Chloride
- Chloride Channel Activators
- Activators, Chloride Channel
- Channel Activators, Chloride
- Chloride Channel Stimulators
- Channel Stimulators, Chloride
- Stimulators, Chloride Channel
|
Below are MeSH descriptors whose meaning is more general than "Chloride Channel Agonists".
Below are MeSH descriptors whose meaning is more specific than "Chloride Channel Agonists".
This graph shows the total number of publications written about "Chloride Channel Agonists" by people in this website by year, and whether "Chloride Channel Agonists" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 0 | 1 | 1 | | 2012 | 0 | 1 | 1 | | 2015 | 0 | 2 | 2 | | 2016 | 1 | 1 | 2 | | 2017 | 1 | 2 | 3 | | 2018 | 3 | 2 | 5 | | 2019 | 4 | 3 | 7 | | 2020 | 5 | 0 | 5 | | 2021 | 7 | 3 | 10 | | 2022 | 0 | 3 | 3 | | 2023 | 0 | 6 | 6 | | 2024 | 1 | 5 | 6 | | 2025 | 2 | 11 | 13 | | 2026 | 2 | 5 | 7 |
To return to the timeline, click here.
Below are the most recent publications written about "Chloride Channel Agonists" by people in Profiles.
-
Zemanick ET, Graeber SY, Castellani C, Cutting GR, Fajac I, Konstan MW, Linnemann RW, McKone EF, Metcalf A, Solomon GM, Taylor-Cousar JL, Mayer-Hamblett N, Mall MA. The role of sweat chloride in determining CFTR protein restoration in people with cystic fibrosis. Lancet Respir Med. 2026 Aug; 14(8):704-716.
-
Matheson AM, Prather E, Willmering MM, Mata J, Santyr G, Ratjen FA, Kramer EL, Cleveland ZI, Woods JC. Lung mucus burden and treatment response assessed by MRI in the post-modulator era. J Cyst Fibros. 2026 Jul; 25(4):711-717.
-
Downey DG, Houston C, Mayer-Hamblett N, Taylor-Cousar JL, Taggart CC. Contributors to the heterogeneity of response to CFTR modulators. Lancet Respir Med. 2026 Aug; 14(8):717-729.
-
Van Braeckel E, Braun AT, Simmonds NJ, Barry PJ, Davies JC, Egan ME, Lapey A, Mall MA, McKone EF, Peckham D, Proesmans M, Ramsey B, Santamaria SV, Smith D, Taylor-Cousar JL, Tullis E, De Wachter E, Withers N, Ahluwalia N, Conner S, Jennings M, Lou Y, Weinstock TG, Keating D. Effects of Elexacaftor/Tezacaftor/Ivacaftor on cough frequency, physical activity patterns, and sleep quality in adolescents and adults with cystic fibrosis. J Cyst Fibros. 2026 Jul; 25(4):682-688.
-
Green N, Vu P, Xie J, Schwarzenberg SJ, Freedman S, Narkewicz M, Pittman J, Ratjen F, Rosenfeld M, Pope C, Duong J, Hoffman L, Heltshe S, Lusman SS. Impact of elexacaftor/tezacaftor/ivacaftor on gastrointestinal outcomes, inflammation, exocrine pancreatic function and fat malabsorption: Report of PROMISE pediatric substudy. J Cyst Fibros. 2026 May; 25(3):489-494.
-
Sagel SD, Poore TS, Wagner BD, Xie J, Heltshe SL, Cross M, Bratcher PE, Taylor-Cousar JL, Wilson A, McBennett K, Morgan SJ, Singh PK, Nichols DP, Kelly A, Solomon GM. Long-term reductions in inflammation in people with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor. Ann Am Thorac Soc. 2026 02 01; 23(2):241-251.
-
Shirley Bezerra M, Zemel BS, Gallop RJ, Walega R, Donaldson SH, Frederick CA, Freedman SD, Gelfond D, Hoffman LR, Narkewicz MR, Rowe SM, Sagel SD, Schwarzenberg SJ, Solomon GM, Chan CL, Kelly A. Longitudinal changes in bone mineral density after initiation of elexacaftor-tezacaftor-ivacaftor in youth and adults with cystic fibrosis: PROMISE-ENDO. J Cyst Fibros. 2026 May; 25(3):457-465.
-
Lyons ER, Vigers T, Simoni M, Lynn C, Muther E. Body Image Perceptions and Elexacaftor/Tezacaftor/Ivacaftor (ETI) Use in Adolescents and Young Adults Living With Cystic Fibrosis. Pediatr Pulmonol. 2025 Dec; 60(12):e71418.
-
Sagel SD, Vu P, Heltshe SL, Solomon GM, Kelly A, Pittman J, Rosenfeld M, Ratjen F. Elexacaftor/tezacaftor/ivacaftor is associated with long-term reduction in use of chronic respiratory therapies in cystic fibrosis. J Cyst Fibros. 2026 May; 25(3):450-456.
-
Ye W, Magee JC, Huang S, Leung DH, Bozic M, Stoll J, C Ling S, Paranjape SM, Karnsakul W, Jay Freeman A, Schwarzenberg SJ, Palermo J, Alonso E, Green N, Masand P, Karmazyn B, Harned R, Navarro OM, Siegel MJ, Towbin A, Alazraki A, Otto RK, Nicholas JL, Narkewicz MR. Impact of elexacaftor/tezacaftor/ivacaftor on biomarkers of cystic fibrosis hepatobiliary involvement in the PUSH study. J Pediatr Gastroenterol Nutr. 2026 Feb; 82(2):350-357.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|